Solid 17% organic growth in Q2, and margin surprisingly strong. We raise adj. EBITA by 6-5% on better cost run-rate. Re-rated again, but still more upside to fair multiples - keep BUY
Q2e: 19% org. sales growth and 1.5pp adj. EBITA margin uplift y-o-y. Minor organic revisions, negative FX partly offset by M&A. BUY the dip, multiple contraction on a largely unchanged outlook.
Decent across the board but slightly lower org. top line makes us lower our '24e organic growth assumptions by 2pp. Limited total revisions on better FX - keep BUY at 21x '25e EV/EBIT.
Underlying top-line growth is accelerating, +25% y-o-y Opex up 11% q-o-q main concern, but GM slightly better Retain HOLD as we still await a better entry point